The clinical effect of mesalazine combined with ligustrazine in treating ulcerative colitis
Zhou Maojing
Abstract
Zhou Maojing
Abstract
0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.
Key concepts: Mesalazine, Medicine, Ulcerative colitis, Gastroenterology, Internal medicine, Colitis, Clinical efficacy, Disease